To determine whether fibrinogen concentrate infusion dosed to achieve a plasma fibrinogen level of 2.5 g/L in high-risk cardiac surgery patients with intraoperative bleeding reduces intraoperative blood loss.
Background: Acute heart failure (AHF) after ST-segment elevation myocardial infarction (STEMI) is usually treated with inotropic support or vasoactive medications.
Background: Recent clinical trials have shown that pulmonary artery pressure-guided therapy via the CardioMEMS™ system reduces the risk of recurrent hospitalizations in chronic heart failure (HF) patients.
The HeartMate 3 Left Ventricular Assist System (LVAS) (St. Jude Medical Inc., St Paul, MN) with full magnetic levitation allows for wide and consistent blood flow paths and an artificial pulse designed for enhanced hemocompatibility.
Objective: Simendan is a calcium sensitizer that enhances myocardial contractility but does not affect ventricular diastole.
The primary aim of this review was to examine the clinical outcomes of levosimendan versus placebo in patients with preoperative low LVEF ≤ 50% undergoing cardiac surgery
Nuwellis, Inc. a commercial-stage company focused on transforming the lives of people with fluid overload, announced the publication of key clinical data supporting the use of ultrafiltration with the Aquadex FlexFlow System in high-risk postoperative coronary artery bypass grafting (CABG) patients in the Journal of Cardiac Surgery
Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality.
As a calcium sensitizer and inodilator that augments cardiac contractility without increasing myocardial oxygen demand or exacerbating ischaemia, levosimendan may be well configured to deliver inotropic support in cases of acute heart failure (AHF).
Mechanical circulatory support improves survival and quality of life in selected patients with advanced heart failure.